 The study is a randomized, double-blind placebo controlled study involving a group of 42 mild asthmatics. Subjects will be randomized 1:1 to omalizumab a humanized monoclonal anti-IgE antibody or placebo for 8 weeks and then inoculated with rhinovirus strain-16 produced under GMP conditions and approved for this research by the FDA. Clinical and laboratory mechanistic data will be evaluated for 8 weeks before and for 4 weeks after the virus challenge. 